Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZODIAC: Zibotentan/Dapagliflozin in CKD with High Proteinuria
NCT06942910Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- May 2025
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of zibotentan in chronic kidney disease (CKD), sponsored by AstraZeneca. Started May 2025; status: active, not recruiting.
02
Drugs
zibotentan
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT06942910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06942910.